At week 24 , 55.4 % , 62.3 % , 41.5 % , 38.8 % , and 32.3 % of subjects with baseline HbA1c 7 % ( 53 mmol/mol ) reached HbA1c < 7 % with empagliflozin 25 mg/linagliptin 5 mg , empagliflozin 10 mg/linagliptin 5 mg , empagliflozin 25 mg , empagliflozin 10 mg , and linagliptin 5 mg , respectively .